Kiniksa Pharmaceuticals Q4 EPS $0.35 Beats $(0.14) Estimate, Sales $83.39M Beat $72.02M Estimate
Portfolio Pulse from Happy Mohamed
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported Q4 earnings of $0.35 per share, surpassing the $(0.14) estimate, marking a 350% beat and a 483.33% increase from last year's $0.06. Sales reached $83.39M, exceeding the $72.02M estimate by 15.79% and showing a 34.76% increase from the previous year.
February 28, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kiniksa Pharmaceuticals reported a significant beat on both earnings and sales estimates for Q4, with earnings per share at $0.35 against a $(0.14) estimate and sales of $83.39M against a $72.02M estimate.
The substantial beat on both earnings per share and sales estimates for Kiniksa Pharmaceuticals indicates strong financial health and operational efficiency, likely leading to positive investor sentiment and potential short-term stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100